Reply to Starting With a Lower Daily Dose of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase: Less Is More, or Is It?

Cancer - United States
doi 10.1002/cncr.31683
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Starting With a Lower Daily Dose of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase: Less Is More, or Is It?

Cancer
Cancer ResearchOncology
2018English

Long-Term Follow-Up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2019English

Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib

Blood and Lymphatic Cancer: Targets and Therapy
2014English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Long-Term Efficacy and Safety of Dasatinib in Patients With Chronic Myeloid Leukemia in Accelerated Phase Who Are Resistant to or Intolerant of Imatinib

Blood Cancer Journal
OncologyHematology
2018English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Telomere Length Shortening Is Associated With Treatment-Free Remission in Chronic Myeloid Leukemia Patients

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2016English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy